Differentiation-focused CRISPR Screen identifies LSD1 and Menin as combination therapy targets that induce terminal differentiation in AML

以分化为重点的 CRISPR 筛选将 LSD1 和 Menin 确定为诱导 AML 终末分化的联合治疗靶点

• 批准号: 10678478
• 负责人: Maria Fernanda Carrera Rodriguez
• 金额: $ 4.77万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10678478
• 关键词: Accounting; Acute Myelocytic Leukemia; Adopted; Automobile Driving; Biological Assay; Blood; CD86 gene; CRISPR screen; CRISPR/Cas technology; Cell Cycle; Cell Differentiation process; Cell model; Cells; Cellular Assay; Cessation of life; ChIP-seq; Characteristics; Chromatin; Clinical Trials; Clustered Regularly Interspaced Short Palindromic Repeats; Combinatorics; Combined Modality Therapy; Data; Differentiated Gene; Differentiation Therapy; Disease; Disease remission; Epigenetic Process; Experimental Models; Genes; Genomics; Hematopoietic Neoplasms; Human; Human Cell Line; ITGAM gene; Individual; KDM1A gene; Libraries; MLL-rearranged leukemia; Malignant Neoplasms; Menin; Methodology; Methods; Modeling; Molecular; Mus; Myelogenous; Oncogenes; Pathway interactions; Patients; Pharmacologic Substance; Phenotype; Prognosis; Progranulocytes; Proliferating; Proteins; Regulation; Relapse; Reporting; Repression; Rest; Role; Sampling; Surface; Testing; Therapeutic; Transcription Coactivator; Transcription Repressor; Treatment Efficacy; Xenograft Model; acute myeloid leukemia cell; chemotherapy; cofactor; cohort; combinatorial; cytotoxicity; derepression; differential expression; epigenomics; experimental study; gene repression; histological stains; histone demethylase; improved; in vivo; inhibitor; interest; leukemia; mouse model; novel; pharmacologic; preclinical efficacy; prevent; progenitor; programs; self-renewal; small molecule; small molecule inhibitor; standard of care; stem; stemness; synergism; targeted treatment; therapeutic evaluation; transcription factor; transcriptome sequencing; transcriptomics; transplant model; treatment strategy

Project Summary Acute myeloid leukemia (AML) is a lethal blood cancer characterized by a differentiation “block” that prevents myeloid progenitor maturation resulting in uncontrolled proliferation. Chemotherapy, the current standard of care, is often ineffective and can result in cytotoxicity and relapse. New treatment options are desperately needed to treat AML’s poor prognosis. Differentiation therapy is a novel method that aims to reactivate latent maturation programs and induce cell cycle exit. This therapeutic strategy is curative in the promyelocytic (APL) AML subtype but underexplored in other AMLs. Epigenetic factors help sustain the characteristic AML differentiation block. The demethylase LSD1 has emerged as a promising target for differentiation therapy. Pharmacologic inhibition of LSD1 (LSD1i) induces cellular differentiation in many AML subtypes. However, the extent of differentiation varies between AML models, with a modest effect in aggressive AML models. Therefore, LSD1i will not induce terminal differentiation as a monoagent treatment. We hypothesized that targeting additional epigenetic regulators simultaneously with LSD1i may induce complete, terminal differentiation and lead to disease remission. To identify potentiators of LSD1i, we conducted CRISPR gain-of-differentiation screens with a chromatin-focused sgRNA library in multiple AML cell models with or without LSD1i co-treatment. These screens unveiled a synergistic induction of differentiation when KO of MEN1 is combined with LSD1i. I confirmed that combinatorial small molecule inhibition of LSD1 and MEN1 induces differentiation and reduces proliferation most commonly in MLL-rearranged AMLs, and to a lesser extent in selected MLL-wild type AMLs. This proposal has two aims: First, I will test the therapeutic potential of targeting MEN1 in combination with LSD1 inhibitors in primary patient samples ex vivo and in patient-derived AML transplant models. Patient samples will be treated with a MEN1 inhibitor in combination with LSD1 inhibitors, and effects on differentiation and proliferation will be quantified. Secondly, I will determine the epigenomic mechanisms by which MEN1 and LSD1 inhibition synergize to induce terminal differentiation, and then test whether these mechanisms are conserved in primary patient samples.

项目概要 急性髓系白血病 (AML) 是一种致命的血液癌症，其特征是分化“阻断”，可阻止 骨髓祖细胞成熟导致不受控制的增殖，目前的治疗标准是化疗。 通常无效，并可能导致细胞毒性和复发，迫切需要新的治疗方案。 治疗 AML 的不良预后是一种旨在重新激活潜在成熟的新方法。 这种治疗策略对早幼粒细胞 (APL) AML 亚型具有疗效。 但在其他 AML 中尚未得到充分研究，表观遗传因素有助于维持特有的 AML 分化障碍。 去甲基化酶 LSD1 已成为分化治疗的一个有前景的靶点。 LSD1 (LSD1i) 可诱导许多 AML 亚型的细胞分化，但分化程度有限。 不同的 AML 模型存在差异，对侵袭性 AML 模型的影响较小，因此 LSD1i 不会诱导。 我们开发了针对额外表观遗传的终末分化治疗。 与 LSD1i 同时存在的调节因子可能诱导完全的终末分化并导致疾病 为了鉴定 LSD1i 的增强剂，我们使用 CRISPR 进行了分化增益筛选。 在有或没有 LSD1i 联合治疗的多个 AML 细胞模型中以染色质为中心的 sgRNA 文库。 揭示了当 MEN1 的 KO 与 LSD1i 组合时协同诱导分化。 LSD1 和 MEN1 的组合小分子抑制最能诱导分化并减少增殖 常见于 MLL 重排 AML，并在较小程度上用于选定的 MLL 野生型 AML。 有两个目标：首先，我将测试针对 MEN1 与 LSD1 抑制剂联合治疗的治疗潜力 体外和患者来源的 AML 移植模型中的主要患者样本将得到处理。 MEN1 抑制剂与 LSD1 抑制剂联合使用，对分化和增殖的影响将 其次，我将确定 MEN1 和 LSD1 抑制协同作用的表观基因组机制。 诱导终末分化，然后测试这些机制在原发患者中是否保守 样品。